Home / Europe / Switzerland / Corporate / M&A

Corporate / M&A

Whether you are planning a merger as part of your growth strategy, thinking about diversifying into new sectors or looking for new funding options such as non-bank lending or through equity investment, our experts offer you the right mix of legal and commercial advice. Having lawyers who think and act beyond their traditional role and seek to add value can help you secure the competitive edge you need in an ever-changing business environment. Our international team of more than 700 corporate lawyers in 43 countries worldwide can assist you in all aspects of corporate law and M&A, both domestically and internationally.

Whatever your size, a large publicly listed company or a small privately owned business, we can deliver a tailored, commercial, cost effective solution for you, covering areas such as M&A, private equity, equity capital markets, outsourcing, group restructuring and privatisations. Our cross-border teams consist of experts from all practice areas and sectors such as banking, consumer products, energy, infrastructure, insurance, lifesciences, real estate and construction, hotels and leisure, technology and media. This allows us to understand your specific issues for a transaction and provide you with advice within context, saving time and money and allows us to pinpoint your real commercial issues and risks in a transaction.

Choose area

Capital Markets and Public M&A
Your partner for Capital Market and Public M&A transactions in SwitzerlandAre you active on the Swiss capital market? If so, our capital market lawyer

Feed

26/01/2023
CMS ad­vises Lab14 GmbH on the ac­quis­i­tion of a ma­jor­ity stake in Nanos­urf...
Lab14 GmbH, a port­fo­lio com­pany of RS­BG SE, the in­vest­ment com­pany of the RAG-Found­a­tion, ac­quires a ma­jor­ity stake in Li­estal-based Nanos­urf AG. Zurich, 26 Janu­ary 2023 
26/01/2023
Re­vi­sion of cor­por­ate law
26 Janu­ary 2023On 1 Janu­ary 2023, after a long last­ing polit­ic­al pro­cess, the new cor­por­ate law (amend­ment of the Swiss Code of Ob­lig­a­tions) has come in­to force. In ad­di­tion to cla­ri­fic­a­tions and ad­min­is­trat­ive sim­pli­fic­a­tions, the re­vi­sion of the cor­por­ate law aims, among oth­er things, to make the in­cor­por­a­tion and cap­it­al reg­u­la­tions more flex­ible and to align them with the ac­count­ing law, to mod­ern­ize the pro­vi­sions re­gard­ing the board of dir­ect­ors and the gen­er­al meet­ing of share­hold­ers, and to strengthen share­hold­er rights. In ad­di­tion, the re­vised law ex­pressly al­lows the in­tro­duc­tion of an ar­bit­ra­tion clause in the art­icles of as­so­ci­ation.Be­low you will find an over­view of the most im­port­ant changes.
15/01/2023
CMS ad­vises the own­er fam­ily on the sale of a ma­jor­ity stake in SCHURTER...
The Swiss in­vestor Capvis, which spe­cial­ises in me­di­um-sized in­vest­ments, ac­quires a ma­jor­ity stake in the Lu­cerne-based SCHURTER Group. The found­ing and pre­vi­ous own­er fam­ily con­tin­ues to hold a stake in the com­pany and is rep­res­en­ted on the board of dir­ect­ors by Thomas Schurter.
04/01/2023
CMS ad­vises US tech­no­logy com­pany Bruker on en­ter­ing in­to a cor­por­ate stra­tegic...
Zurich, 4 Janu­ary 2023 Bruker Cor­por­a­tion, a NAS­DAQ-lis­ted US tech com­pany, has entered in­to a part­ner­ship with Swiss firm Biognosys AG to de­liv­er ad­vanced pro­teo­m­ics CRO ser­vices for US bio­pharma and bio­mark­er cus­tom­ers. As part of the part­ner­ship, Bruker has made a ma­jor­ity-own­er­ship in­vest­ment in Biognosys AG. Biognosys is a lead­er in the de­vel­op­ment of pro­teo­m­ics tech­no­lo­gies and solu­tions for phar­ma­ceut­ic­al and bi­otech re­search. The stra­tegic part­ner­ship is ex­pec­ted to cre­ate unique syn­er­gies between Biognosys’ port­fo­lio of pro­teo­m­ics ser­vices, soft­ware and kits, and Bruker’s pi­on­eer­ing tim­sTOF plat­form. As a res­ult of the part­ner­ship, Biognosys plans to open its first ad­vanced pro­teo­m­ics CRO ser­vices labor­at­ory in the US. De­tails of the trans­ac­tion were not dis­closed.An in­ter­na­tion­al CMS team headed by Stefan Brunnsch­weiler and Dr Hendrik Hirsch ad­vised Bruker on all leg­al as­pects of the trans­ac­tion. Bruker has also re­lied on the ex­pert­ise of CMS in the past. Pre­vi­ous work by CMS for Bruker Cor­por­a­tion in­cluded provid­ing leg­al ad­vice on the com­pany’s in­vest­ment in PreO­m­ics.CMS Switzer­land­Stefan Brunnsch­weiler, Lead Part­ner, Zurich, Cor­por­ate / M&AAndrea Relly, Seni­or As­so­ci­ate, Cor­por­ate / M&ASamuel Fe­lix Gang, Seni­or As­so­ci­ate, Cor­por­ate / M&APas­cal Stock­er, Seni­or As­so­ci­ate, Cor­por­ate / M&AAnna Mast, As­so­ci­ate, Cor­por­ate / M&ADr Si­mone Brauch­bar Birkhäuser, Part­ner, In­tel­lec­tu­al Prop­er­ty­Mark Ca­gi­enard, Part­ner, Tax­Sarah Keller, Seni­or As­so­ci­ate, Em­ploy­ment & Pen­sion­sHadi Mirzai, Seni­or As­so­ci­ate, Life Sci­ences and Com­pet­i­tion­Valentina Bal­aj, As­so­ci­ate, Reg­u­lat­ory / Com­pli­anceCMS Ger­manyDr Hendrik Hirsch, Lead Part­ner, Frank­furt/Main, Cor­por­ate/M&ADr Ber­rit Roth-Min­gram, Seni­or As­so­ci­ate, Frank­furt/Main, Cor­por­ate/M&ADr Thomas Hirse, Part­ner, Dus­sel­dorf, In­tel­lec­tu­al Prop­er­tyS­ven Krause, Seni­or As­so­ci­ate, Dus­sel­dorf, In­tel­lec­tu­al Prop­erty
21/12/2022
SIX Swiss Ex­change now lists GDRs of Chinese com­pan­ies
Switzer­land and China have es­tab­lished a "Stock Con­nect" pro­gramme en­abling Chinese com­pan­ies lis­ted on the Shang­hai or Shen­zhen stock ex­change to ac­cess the Swiss cap­it­al mar­ket by list­ing Glob­al De­pos­it­ary...
09/12/2022
CMS ad­vises DER Tour­istik Suisse AG on its sale of a stake in RAIL­TOUR...
9. Dezem­ber 2022DER Tour­istik Suisse AG has sold a minor­ity stake in RAIL­TOUR (SUISSE) SA to ÖBB sub­si­di­ary Rail Tours Tour­istik GmbH.With this step, DER Tour­istik Suisse AG aims to ex­pand the rail ex­pert­ise of its sub­si­di­ary RAIL­TOUR (SUISSE) SA in the growth mar­ket for sus­tain­able rail travel. The co­oper­a­tion with ÖBB is also in­ten­ded to strengthen RAIL­TOUR (SUISSE) SA in the de­vel­op­ment of its sales ex­pert­ise and ac­cess to new cus­tom­er groups.DER Tour­istik Suisse AG is a mar­ket-lead­ing Swiss tour­ism com­pany and cov­ers the en­tire spec­trum of the travel world with its tour op­er­at­ors Kuoni, Hel­vetic Tours and spe­cial­ist tour op­er­at­ors. As part of the DER Tour­istik Group, it be­longs to one of the largest travel groups in Europe. A team from CMS Switzer­land and CMS Ger­many, led by part­ner Stephan Wer­len (CMS Switzer­land), ad­vised DER Tour­istik Suisse AG on all leg­al as­pects of the trans­ac­tion.CMS Switzer­land­Dr Stephan Wer­len, Part­ner, Cor­por­ate / M&AAl­ex­an­dra Stock­er, As­so­ci­ate, Cor­por­ate / M&ADa­vid Hürli­mann, Part­ner, TaxJens Lehmann, As­so­ci­ate, TaxDr Dirk Spacek, Part­ner, IP/IT­Marquard Christen, Part­ner, Mer­ger Con­trol­CMS Ger­ma­ny­Chris­toff Hen­rik Soltau, Part­ner, Mer­ger Con­trol
11/11/2022
CMS ad­vises Bruker on its in­vest­ment in Nav­ign­ostics
Bruker Cor­por­a­tion, a NAS­DAQ-lis­ted US tech com­pany in the ana­lyt­ic­al in­stru­ment­a­tion sec­tor, in­vests in Nav­ign­ostics. Bruker led the CHF 7.5 mil­lion seed fin­an­cing round, which was also joined by Think.Health Ven­tures, Ven­tura Bio­med In­vestors and Zürch­er Kan­ton­al­bank.Nav­ign­ostics strives to sup­port the se­lec­tion of tar­geted and im­muno-on­co­logy ther­apies tailored to the tu­mour phen­o­type of in­di­vidu­al can­cer pa­tients by us­ing ar­ti­fi­cial in­tel­li­gence driv­en soft­ware com­bined with single-cell re­solved spa­tial pro­teo­m­ic tu­mour data. The fund­ing will strengthen Nav­ign­ostic­s' abil­ity to col­lab­or­ate with clin­ic­al, bi­o­tech­no­logy and phar­ma­ceut­ic­al part­ners and ac­cel­er­ate the de­vel­op­ment of its first dia­gnost­ic product.A team from CMS Switzer­land, led by part­ner Stefan Brunnsch­weiler, ad­vised Bruker on all leg­al mat­ters of the trans­ac­tion. Bruker is a long­stand­ing CMS cli­ent and has been ad­vised by CMS on sev­er­al ac­quis­i­tions and dis­pos­als in the past.CMS Switzer­land­Stefan Brunnsch­weiler, Part­ner, Cor­por­ate / M&APas­cal Stock­er, As­so­ci­ate, Cor­por­ate / M&ADr Si­mone Brauch­bar Birkhäuser, Coun­sel, In­tel­lec­tu­al Prop­er­ty­Hadi Mirzai, As­so­ci­ate, Life Sci­ences and Com­pet­i­tion­Sarah Keller, As­so­ci­ate, Em­ploy­ment 
10/11/2022
CMS ad­vised DuPont in its M&M Di­vestit­ure to Celanese
 The glob­al in­nov­a­tion lead­er with tech­no­logy-based ma­ter­i­als and solu­tions, DuPont (NYSE: DD), has di­vested on Novem­ber 1, 2022, the ma­jor­ity of its former Mo­bil­ity & Ma­ter­i­als seg­ment (the “M&M Di­vestit­ure”) to Celanese.Dr Pas­cal Favre led the Geneva team of CMS Switzer­land who ad­vised DuPont Switzer­land and handled all as­pects of the Swiss com­pon­ent of the M&M Di­vestit­ure. The team fur­ther com­prised Audrey Dur­and, Kev­in Mar­cato and Dav­id Müller.For more in­form­a­tion on the trans­ac­tion, please vis­it:  ht­tps://www.dupont.com/news/dupont-com­pletes-mo­bil­ity-ma­ter­i­als-di­vestit­ure-to-celanese.html
02/11/2022
CMS ad­vised ISS on the ac­quis­i­tion of Liv­it FM Ser­vices AG
The lead­ing fa­cil­ity man­age­ment and work­place ex­per­i­ence com­pany ISS has ac­quired Liv­it FM Ser­vices AG from its pre­vi­ous par­ent com­pany Liv­it AG. Liv­it FM Ser­vices AG looks after a large pro­por­tion of Swiss Life prop­er­ties in Switzer­land. The com­pany has over 670 em­ploy­ees. The takeover of Liv­it FM Ser­vices AG is a stra­tegic ac­quis­i­tion that strengthens ISS Switzer­land's mar­ket po­s­i­tion. The trans­ac­tion will en­able ISS to ex­pand and de­vel­op its ser­vice de­liv­ery to the real es­tate in­dustry seg­ment. The in­teg­ra­tion of the ac­quired com­pany is ex­pec­ted to be com­pleted in the first quarter of 2023. Liv­it FM Ser­vices AG will op­er­ate un­der the ISS brand in the fu­ture.A team of CMS led by Dr Daniel Jenny com­pre­hens­ively ad­vised ISS on all leg­al mat­ters of this trans­ac­tion.CMS Switzer­land­Dr Daniel Jenny, Part­ner, Cor­por­ate/M&ADr Ferdin­and Blezinger, As­so­ci­ate, Cor­por­ate/M&AFlori­an Jung, As­so­ci­ate, Cor­por­ate/M&AAl­ex­an­dra Stock­er, As­so­ci­ate, Cor­por­ate/M&AReto Hun­sper­ger, Part­ner, Com­mer­cialDr Mar­jolaine Jakob, Part­ner, Com­mer­cial­Christina Winter, As­so­ci­ate, Em­ploy­men­tHelena Loretan, As­so­ci­ate, Real Es­tate­M­ark Ca­gi­enard, Part­ner, Tax
28/10/2022
CMS ad­vises on joint ven­ture between Voigt Hold­ing AG and PHOENIX Pharma...
Zurich, 28 Oc­to­ber 2022The Voigt Group and PHOENIX Pharma Switzer­land have agreed to merge their sub­si­di­ar­ies, each act­ive in phar­ma­ceut­ic­al lo­gist­ics and phar­ma­ceut­ic­al whole­sale sec­tors re­spect­ively, in­to a 50/50 joint ven­ture. The two long-es­tab­lished and fin­an­cially sound com­pan­ies are an ideal fit with com­ple­ment­ary of­fer­ings and com­pet­en­cies in the sup­ply chain.Sub­ject to ap­prov­al by the Swiss Com­pet­i­tion Com­mis­sion, this joint ven­ture will cre­ate a new, com­pet­ent and sus­tain­able play­er in the sup­ply chain of the Swiss health­care mar­ket.A CMS Switzer­land team led by Dr Patrick Som­mer provided com­pre­hens­ive leg­al ad­vice to Voigt Group on this joint ven­ture.CMS Switzer­land: Dr. Patrick Som­mer, Part­ner, Lead, Cor­por­ate / M&A, Com­pet­i­tion & EU­Alain Raemy, Part­ner, Cor­por­ate / M&AM­arquard Christen, Part­ner, Com­pet­i­tion & EU­Dirk Spacek, Part­ner, In­tel­lec­tu­al Prop­er­ty­Dr Si­mone Brauch­bar Birkhäuser, Coun­sel, In­tel­lec­tu­al Prop­er­ty­Hadi Mirzai, As­so­ci­ate, Life Sci­ences, Com­pet­i­tion & EUAl­ex­an­dra Stock­er, As­so­ci­ate, Cor­por­ate / M&AAnna Mast, As­so­ci­ate, Cor­por­ate / M&ADr. Mat­thi­as Kuert, As­so­ci­ate, Bank­ing & Fin­an­ceTho­mas Zweifel, As­so­ci­ate, Real Es­tat­e­Christina Winter, As­so­ci­ate, Em­ploy­ment
13/10/2022
Law and reg­u­la­tion of private place­ment of com­mon stock in Switzer­land
1. Pro­spect­us re­quire­ment Of­fer to the pub­lic (i.e. an of­fer to an un­lim­ited num­ber of per­sons con­cern­ing the sub­scrip­tion for new se­cur­it­ies or the pur­chase of se­cur­it­ies in Switzer­land).Ap­plic­a­tion...
Comparable
04/10/2022
CMS ad­vised Vista Au­gen­prax­is & Klinik­en on the ac­quis­i­tion of AV­ANTI,...
Vista Klinik Hold­ing AG, dom­i­ciled in Bin­nin­gen (Switzer­land), ac­quired AV­ANTI, Centro Ti­cinese di chirur­gia am­bu­lat­oriale SA (AV­ANTI) on 15 Ju­ly 2022 and is now present in the can­ton of Ti­cino for the first time. AV­ANTI, which was foun­ded in 2007, has three op­er­at­ing rooms with a total area of 605 square metres, as well as a con­vales­cence area and an oph­thal­mo­logy prac­tice spe­cial­ising in ret­in­al treat­ments. AV­ANTI per­forms about 5,000 oph­thal­mo­lo­gic­al op­er­a­tions an­nu­ally. There will be no changes with re­gard to the staff, as they will con­tin­ue to work for AV­ANTI.Fur­ther­more, CMS ad­vised Vista Klinik Hold­ing AG on two oth­er trans­ac­tions in the middle of this year: The pur­chase of all shares in an eye centre with two as­so­ci­ated prac­tices in the can­tons of Aar­gau and Zurich was suc­cess­fully com­pleted, and an­oth­er eye prac­tice in the can­ton of Gris­ons was ac­quired as part of an as­set deal.Vista Au­gen­prax­en & Klinik­en was foun­ded over 30 years ago and con­sists of a net­work of ex­per­i­enced oph­thal­mo­lo­gists and spe­cial­ists with a fo­cus on north­west­ern Switzer­land and the Zurich area. With the afore­men­tioned ac­quis­i­tions, the num­ber of loc­a­tions will be fur­ther in­creased so that the ser­vices of Vista Au­gen­prax­en & Klinik­en can now also be ac­cessed in the Itali­an-speak­ing part of Switzer­land. The range of ser­vices offered by Vista Au­gen­prax­en & Klinik­en in­cludes all treat­ments as well as spe­cial­isa­tions in the field of ret­ina and catar­act op­er­a­tions, the ther­apy of mac­u­lar de­gen­er­a­tion and the cor­rec­tion of re­fract­ive er­rors. In or­der to keep up with the in­ter­na­tion­al state of sci­ence, Vista Au­gen­prax­en & Klinik­en in­vests in for­ward-look­ing re­search activ­it­ies, in the con­tinu­ous train­ing of all em­ploy­ees and in the ex­pan­sion and in­vent­ory of prac­tices and clin­ics.A team of CMS Switzer­land, led by Stefan Brunnsch­weiler and Fran­ziska Ham­mer, ad­vised Vista Au­gen­prax­en & Klinik­en on all leg­al mat­ters of the trans­ac­tions.CMS Switzer­land­Stefan Brunnsch­weiler, Part­ner, Cor­por­ate / M&AFran­ziska Ham­mer, Coun­sel, Cor­por­ate / M&ASamuel Fe­lix Gang, As­so­ci­ate, Cor­por­ate / M&AAnna Mast, As­so­ci­ate, Cor­por­ate / M&AMiryam Meile, As­so­ci­ate, Em­ploy­ment­Mar­zia Schil­leci, As­so­ci­ate, Lit­ig­a­tion­Premton Haziri, At­tor­ney Train­ee